Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis

References

• Ahn, J., et al., 2008. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. Journal of hepatology, 49 (6), 1019–1028.
   PubMed Web of Science ®Google Scholar
• Ajmo, J.M., et al., 2008. Resveratrol alleviates alcoholic fatty liver in mice. American journal of physiology. gastrointestinal and liver physiology, 295 (4), G833–G842.
   PubMed Web of Science ®Google Scholar
• Akhtar, D.H., et al., 2019. Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease. Journal of clinical and translational hepatology, 7 (4), 362–370.
   PubMed Web of Science ®Google Scholar
• Alberdi, G., et al., 2013. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition, 29 (3), 562–567.
   PubMed Web of Science ®Google Scholar
• Andrade, J.M., et al., 2014. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition, 30 (7–8), 915–919.
   PubMed Web of Science ®Google Scholar
• Asrih, M., and Jornayvaz, F.R., 2013. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. The journal of endocrinology, 218 (3), R25–R36.
   PubMed Web of Science ®Google Scholar
• Boshra, S.A., 2020. Resveratrol modulates miR-34a in cardiotoxicity induced by isoproterenol. Journal of medicinal food, 23 (6), 593–599.
   PubMed Web of Science ®Google Scholar
• Bujanda, L., et al., 2008. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC gastroenterology, 8 (1), 40.
   PubMedGoogle Scholar
• Buzzetti, E., Pinzani, M., and Tsochatzis, E.A., 2016. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)). Metabolism: clinical and experimental, 65 (8), 1038–1048.
   PubMed Web of Science ®Google Scholar
• Castro, R.E., et al., 2013. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. Journal of hepatology, 58 (1), 119–125.
   PubMed Web of Science ®Google Scholar
• Cermelli, S., et al., 2011. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One, 6 (8), e23937.
   PubMed Web of Science ®Google Scholar
• Chalkiadaki, A., and Guarente, L., 2012. High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell metabolism, 16 (2), 180–188.
   PubMed Web of Science ®Google Scholar
• Chen, D., et al., 2008. Tissue-specific regulation of SIRT1 by calorie restriction. Genes & development, 22 (13), 1753–1757.
   PubMed Web of Science ®Google Scholar
• Cheung, O., et al., 2008. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology, 48 (6), 1810–1820.
   PubMed Web of Science ®Google Scholar
• Cho, S.J., Jung, U.J., and Choi, M.S., 2012. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. The British journal of nutrition, 108 (12), 2166–2175.
   PubMed Web of Science ®Google Scholar
• Cohen, J.C., Horton, J.D., and Hobbs, H.H., 2011. Human fatty liver disease: old questions and new insights. Science, 332 (6037), 1519–1523.
   PubMed Web of Science ®Google Scholar
• Colak, Y., et al., 2011. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Medical science monitor, 17 (5), HY5–HY9.
   PubMed Web of Science ®Google Scholar
• Colak, Y., et al., 2014. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. Journal of gastrointestinal and liver diseases, 23 (3), 311–319.
   PubMed Web of Science ®Google Scholar
• de Ligt, M., Timmers, S., and Schrauwen, P., 2015. Resveratrol and obesity: can resveratrol relieve metabolic disturbances. Biochimica et biophysica acta, 1852 (6), 1137–1144.
   PubMed Web of Science ®Google Scholar
• Deng, X.Q., Chen, L.L., and Li, N.X., 2007. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver international, 27 (5), 708–715.
   PubMed Web of Science ®Google Scholar
• Ding, J., et al., 2015. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Scientific reports, 5, 13729.
   PubMed Web of Science ®Google Scholar
• Ding, R.B., Bao, J., and Deng, C.X., 2017. Emerging roles of SIRT1 in fatty liver diseases. International journal of biological sciences, 13 (7), 852–867.
   PubMed Web of Science ®Google Scholar
• Ding, S., et al., 2017a. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PLoS One, 12 (8), e0183541.
   PubMed Web of Science ®Google Scholar
• Dongiovanni, P., et al., 2018. miRNA Signature in NAFLD: a turning point for a non-invasive diagnosis. International journal of molecular sciences, 19 (12), 3966.
   PubMed Web of Science ®Google Scholar
• Elhence, A., and Shalimar 2020. Treatment of non-alcoholic fatty liver disease – current perspectives. Indian journal of gastroenterology, 39 (1), 22–31.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh, F., Hekmatdoost, A., and Adibi, P., 2015. Resveratrol and liver: a systematic review. Journal of research in medical sciences, 20 (8), 797–810.
   PubMed Web of Science ®Google Scholar
• Friedman, S.L., et al., 2018. Mechanisms of NAFLD development and therapeutic strategies. Nature medicine, 24 (7), 908–922.
   PubMed Web of Science ®Google Scholar
• Fullerton, M.D., and Steinberg, G.R., 2010. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes, 59 (3), 551–553.
   PubMed Web of Science ®Google Scholar
• Godoy-Matos, A.F., Silva Júnior, W.S., and Valerio, C.M., 2020. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & metabolic syndrome, 12 (60), 60.
   PubMedGoogle Scholar
• Gomes, A.P., et al., 2012. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochimica et biophysica acta, 1822 (2), 185–195.
   PubMed Web of Science ®Google Scholar
• Gomes, A.R., et al., 2016. Sirtuin1 (SIRT1) in the acetylation of downstream target proteins. Methods in molecular biology, 1436, 169–188.
   PubMedGoogle Scholar
• Horton, J.D., Goldstein, J.L., and Brown, M.S., 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. The journal of clinical investigation, 109 (9), 1125–1131.
   PubMed Web of Science ®Google Scholar
• Hosseini, H., et al., 2020. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. The international journal of biochemistry & cell biology, 119, 105667.
   PubMed Web of Science ®Google Scholar
• Howitz, K.T., et al., 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425 (6954), 191–196.
   PubMed Web of Science ®Google Scholar
• Hu, P., Zhao, L., and Chen, J., 2015. Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. European journal of nutrition, 54 (4), 569–579.
   PubMed Web of Science ®Google Scholar
• Huang, Y., et al., 2020. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway. Applied physiology, nutrition, and metabolism, 45 (3), 227–239.
   PubMed Web of Science ®Google Scholar
• Izdebska, M., et al., 2017. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. Canadian journal of physiology and pharmacology, 95 (12), 1442–1453.
   PubMed Web of Science ®Google Scholar
• Izzo, C., et al., 2021. The role of resveratrol in liver disease: a comprehensive review from in vitro to clinical trials. Nutrients, 13 (3), 933.
   PubMed Web of Science ®Google Scholar
• Jakubczyk, K., et al., 2020. Effects of resveratrol supplementation in patients with non-alcoholic fatty liver disease – a meta-analysis. Nutrients, 12 (8), 2435.
   PubMed Web of Science ®Google Scholar
• Jia, N., et al., 2018. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb.) Makino treated mice. Nutrition & metabolism, 15 (86), 86.
   PubMedGoogle Scholar
• Jones, P.H., et al., 2019. Over-expression of miR-34c leads to early-life visceral fat accumulation and insulin resistance. Scientific reports, 9 (1), 13844.
   PubMedGoogle Scholar
• Ju, U.I., et al., 2020. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment. Cell death & disease, 11 (4), 283.
   PubMed Web of Science ®Google Scholar
• Kaur, S., and Kumar, S., 2020. Crosstalk between food components and microRNAs: Rolein metabolism, nutrition, health and diseases. Integrative food, nutrition and metabolism, 7, 1–11.
   Google Scholar
• Kitade, H., et al., 2017. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients, 9 (4), 387.
   PubMed Web of Science ®Google Scholar
• Kořínková, L., et al., 2020. Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides. Frontiers in endocrinology, 11, 597583.
   PubMed Web of Science ®Google Scholar
• Kosgei, V.J., et al., 2020. Sirt1-PPARS cross-talk in complex metabolic diseases and inherited disorders of the one carbon metabolism. Cells, 9 (8), 1882.
   PubMed Web of Science ®Google Scholar
• Lagouge, M., et al., 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127 (6), 1109–1122.
   PubMed Web of Science ®Google Scholar
• Latorre, J., et al., 2017. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. International journal of obesity, 41 (4), 620–630.
   Web of Science ®Google Scholar
• Lavery, C.A., et al., 2016. miR-34a(-/-) mice are susceptible to diet-induced obesity. Obesity, 24 (8), 1741–1751.
   PubMed Web of Science ®Google Scholar
• Li, F., et al., 2019. Adipose-specific knockdown of Sirt1 results in obesity and insulin resistance by promoting exosomes release. Cell cycle, 18 (17), 2067–2082.
   PubMed Web of Science ®Google Scholar
• Li, H., et al., 2012. Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. American journal of physiology endocrinology and metabolism, 303 (10), E1234–E1244.
   PubMed Web of Science ®Google Scholar
• Liu, X.L., et al., 2016. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World journal of gastroenterology, 22 (44), 9844–9852.
   PubMed Web of Science ®Google Scholar
• Mello, T., Materozzi, M., and Galli, A., 2016. PPARs and mitochondrial metabolism: from NAFLD to HCC. PPAR research, 2016, 7403230.
   PubMed Web of Science ®Google Scholar
• Meng, X., et al., 2020. Health benefits and molecular mechanisms of resveratrol: a narrative review. Foods, 9(3), 340.
   PubMed Web of Science ®Google Scholar
• Mongioì, L.M., et al., 2021. The role of resveratrol administration in human obesity. International journal of molecular sciences, 22(9), 4362.
   PubMed Web of Science ®Google Scholar
• Moslehi, A., and Hamidi-Zad, Z., 2018. Role of SREBPs in liver diseases: a mini-review. Journal of clinical and translational hepatology, 6 (3), 332–338.
   PubMed Web of Science ®Google Scholar
• Nguyen, L.T., et al., 2020. Parental SIRT1 overexpression attenuate metabolic disorders due to maternal high-fat feeding. International journal of molecular sciences, 21 (19), 7342.
   PubMed Web of Science ®Google Scholar
• Niederreiter, L., and Tilg, H., 2018. Cytokines and fatty liver diseases. Liver research, 2 (1), 14–20.
   Google Scholar
• Pan, Y., et al., 2019. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. The journal of clinical investigation, 129 (2), 834–849.
   PubMed Web of Science ®Google Scholar
• Park, J.M., et al., 2010. Role of resveratrol in FOXO1-mediated gluconeogenic gene expression in the liver. Biochemical and biophysical research communications, 403 (3–4), 329–334.
   PubMed Web of Science ®Google Scholar
• Parthasarathy, G., Revelo, X., and Malhi, H., 2020. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatology communications, 4 (4), 478–492.
   PubMed Web of Science ®Google Scholar
• Peiyuan, H., et al., 2017. Resveratrol ameliorates experimental alcoholic liver disease by modulating oxidative stress. Evidence-based complementary and alternative medicine, 2017, 4287890.
   PubMed Web of Science ®Google Scholar
• Pfluger, P.T., et al., 2008. Sirt1 protects against high-fat diet-induced metabolic damage. Proceedings of the national academy of sciences of the United States of America, 105 (28), 9793–9798.
   PubMed Web of Science ®Google Scholar
• Phuah, N.H., and Nagoor, N.H., 2014. Regulation of microRNAs by natural agents: new strategies in cancer therapies. BioMed research international, 2014, 804510.
   PubMed Web of Science ®Google Scholar
• Ponugoti, B., et al., 2010. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. The journal of biological chemistry, 285 (44), 33959–33970.
   PubMed Web of Science ®Google Scholar
• Postic, C., and Girard, J., 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. The journal of clinical investigation, 118 (3), 829–838.
   PubMed Web of Science ®Google Scholar
• Price, N.L., et al., 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell metabolism, 15 (5), 675–690.
   PubMed Web of Science ®Google Scholar
• Purushotham, A., et al., 2009. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell metabolism, 9 (4), 327–338.
   PubMed Web of Science ®Google Scholar
• Roza, N.A., et al., 2016. Effect of long-term high-fat diet intake on peripheral insulin sensibility, blood pressure, and renal function in female rats. Food & nutrition research, 60 (1), 28536.
   PubMed Web of Science ®Google Scholar
• Schreuder, T.C., et al., 2008. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World journal of gastroenterology, 14 (16), 2474–2486.
   PubMed Web of Science ®Google Scholar
• Shrestha, N., et al., 2021. Maternal and postnatal high linoleic acid diet impacts lipid metabolism in adult rat offspring in a sex-specific manner. International journal of molecular sciences, 22 (6), 2946.
   PubMed Web of Science ®Google Scholar
• Shulman, G.I., 2014. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. The New England journal of medicine, 371 (12), 1131–1141.
   PubMed Web of Science ®Google Scholar
• Sin, T.K., Yung, B.Y., and Siu, P.M., 2015. Modulation of SIRT1-Foxo1 signaling axis by resveratrol: implications in skeletal muscle aging and insulin resistance. Cellular physiology and biochemistry, 35 (2), 541–552.
   PubMedGoogle Scholar
• Stacchiotti, A., et al., 2019. Melatonin effects on non-alcoholic fatty liver disease are related to microRNA-34a-5p/Sirt1 axis and autophagy. Cells, 8 (9), 1053.
   PubMed Web of Science ®Google Scholar
• Tian, X.F., et al., 2016. Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs. PloS one, 11 (7), e0158657.
   PubMed Web of Science ®Google Scholar
• Tian, Y., et al., 2016. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Molecular and cellular biochemistry, 422 (1–2), 75–84.
   PubMed Web of Science ®Google Scholar
• Torres, L.F., Cogliati, B., and Otton, R., 2019. Green tea prevents NAFLD by modulation of miR-34a and miR-194 expression in a high-fat diet mouse model. Oxidative medicine and cellular longevity, 2019, 4168380.
   PubMed Web of Science ®Google Scholar
• Uyeda, K., and Repa, J.J., 2006. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell metabolism, 4 (2), 107–110.
   PubMed Web of Science ®Google Scholar
• Van De Wier, B., et al., 2017. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Critical reviews in food science and nutrition, 57 (4), 834–855.
   PubMed Web of Science ®Google Scholar
• Vancells Lujan, P., Viñas Esmel, E., and Sacanella Meseguer, E., 2021. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. Nutrients, 13 (5), 1442.
   PubMed Web of Science ®Google Scholar
• Walker, J.M., et al., 2019. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: a pilot randomized, placebo-controlled clinical trial. Journal of clinical and translational research, 4 (2), 122–135.
   PubMedGoogle Scholar
• Wang, G.L., et al., 2009. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochemical and biophysical research communications, 380 (3), 644–649.
   PubMed Web of Science ®Google Scholar
• Wang, L.F., et al., 2017. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway. Lipids in health and disease, 16 (1), 82.
   PubMedGoogle Scholar
• Wang, L., et al., 2020b. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload. Archives of biochemistry and biophysics, 695, 108642.
   PubMed Web of Science ®Google Scholar
• Wang, R.H., et al., 2011. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. The journal of clinical investigation, 121 (11), 4477–4490.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2021a. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 70 (4), 784–795.
   PubMed Web of Science ®Google Scholar
• Wong, R., and Howe, P., 2018. Resveratrol counteracts insulin resistance-potential role of the circulation. Nutrients, 10 (9), 1160.
   PubMed Web of Science ®Google Scholar
• Wu, T., et al., 2014. Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients. Annals of clinical and laboratory science, 44 (4), 410–418.
   PubMed Web of Science ®Google Scholar
• Wu, W.Y., et al., 2020. Pterostilbene improves hepatic lipid accumulation via the MiR-34a/Sirt1/SREBP-1 pathway in fructose-fed rats. Journal of agricultural and food chemistry, 68 (5), 1436–1446.
   PubMed Web of Science ®Google Scholar
• Yang, B., et al., 2016. Resveratrol exerts protective effects on anoxia/reoxygenation injury in cardiomyocytes via miR-34a/Sirt1 signaling pathway. European review for medical and pharmacological sciences, 20 (12), 2734–2741.
   PubMed Web of Science ®Google Scholar
• Yang, S.J., and Lim, Y., 2014. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism: clinical and experimental, 63 (5), 693–701.
   PubMed Web of Science ®Google Scholar
• Yilmaz Demirtas, C., et al., 2018. The effects of resveratrol on hepatic oxidative stress in metabolic syndrome model induced by high fructose diet. Bratislavske lekarske listy, 119 (1), 36–40.
   PubMed Web of Science ®Google Scholar
• Yu, J., et al., 2016. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterology research and practice, 2016, 2862173.
   PubMed Web of Science ®Google Scholar
• Zarfeshani, A., Ngo, S., and Sheppard, A.M., 2015. MicroRNA expression relating to dietary-induced liver steatosis and NASH. Journal of clinical medicine, 4 (11), 1938–1950.
   PubMed Web of Science ®Google Scholar
• Zhang, F., et al., 2021. Resveratrol pretreatment improved heart recovery ability of hyperglycemic bone marrow stem cells transplantation in diabetic myocardial infarction by down-regulating microRNA-34a. Frontiers in pharmacology, 12, 632375.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2017. Sirtuin 1 activation reduces transforming growth factor-β1-induced fibrogenesis and affords organ protection in a model of progressive, experimental kidney and associated cardiac disease. The American journal of pathology, 187 (1), 80–90.
   PubMed Web of Science ®Google Scholar
• Zhou, R., et al., 2018. Resveratrol ameliorates lipid droplet accumulation in liver through a SIRT1/ ATF6-dependent mechanism. Cellular physiology and biochemistry, 51 (5), 2397–2420.
   PubMedGoogle Scholar